Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1
- 30 June 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (13), 4366-4372
- https://doi.org/10.1158/0008-5472.can-10-1769
Abstract
Metformin is a widely prescribed antidiabetic drug associated with a reduced risk of cancer. Many studies show that metformin inhibits cancer cell viability through the inhibition of mTOR. We recently showed that antiproliferative action of metformin in prostate cancer cell lines is not mediated by AMP-activated protein kinase (AMPK). We identified REDD1 (also known as DDIT4 and RTP801), a negative regulator of mTOR, as a new molecular target of metformin. We show that metformin increases REDD1 expression in a p53-dependent manner. REDD1 invalidation, using siRNA or REDD1(-/-) cells, abrogates metformin inhibition of mTOR. Importantly, inhibition of REDD1 reverses metformin-induced cell-cycle arrest and significantly protects from the deleterious effects of metformin on cell transformation. Finally, we show the contribution of p53 in mediating metformin action in prostate cancer cells. These results highlight the p53/REDD1 axis as a new molecular target in anticancer therapy in response to metformin treatment.Keywords
Other Versions
This publication has 20 references indexed in Scilit:
- Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent MannerCell Metabolism, 2010
- Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?Molecular Cancer Therapeutics, 2010
- Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesisProceedings of the National Academy of Sciences of the United States of America, 2010
- Insulin Induces REDD1 Expression through Hypoxia-inducible Factor 1 Activation in AdipocytesOnline Journal of Public Health Informatics, 2010
- Acadesine Kills Chronic Myelogenous Leukemia (CML) Cells through PKC-Dependent Induction of Autophagic Cell DeathPLOS ONE, 2009
- In vitro metformin anti-neoplastic activity in epithelial ovarian cancerGynecologic Oncology, 2008
- The TSC1–TSC2 complex: a molecular switchboard controlling cell growthBiochemical Journal, 2008
- Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14–3–3 shuttlingGenes & Development, 2008
- AMP-activated Protein Kinase Suppresses Protein Synthesis in Rat Skeletal Muscle through Down-regulated Mammalian Target of Rapamycin (mTOR) SignalingOnline Journal of Public Health Informatics, 2002
- Role of AMP-activated protein kinase in mechanism of metformin actionJCI Insight, 2001